Skip to main content
Premium Trial:

Request an Annual Quote

FDA Asks Correlogic Systems for a Meeting on Marketing of its Ovarian Cancer Test

NEW YORK, Feb. 25 (GenomeWeb News) - Steve Gutman, the director of the US Food and Drug Administration's Office of In Vitro  Diagnostic Device Evaluation and Safety, has asked Correlogic Systems to discuss the marketing of the company's test for predicting ovarian cancer, GenomeWeb News  has learned.

 

In the letter to company president Peter Levine, which is dated Feb. 18, Gutman said the test is a device and may be subject to the agency's premarket review requirements.


The test, called OvaCheck, was developed by Correlogic and scientists at the National Cancer Institute and the FDA, and is licensed to clinical lab giants Quest Diagnostics and LabCorp.

 

Correlogic executives were unavailable for immediate comment, the company said.


Click here  to view a copy of the letter, which is posted on the FDA website.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.